Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biomarkers, care, focal, functional, genomics, imaging, molecular, patient-centered, therapy | Leave a comment »
Alan Katz has now published the study with the longest-running follow-up of any study of external beam radiation therapy for prostate cancer among low-risk patients, in this case using SBRT. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 10-year, body, follow-up, SBRT, stereotactic | Leave a comment »
The word “theranostics” is a so-called “portmanteau” word made up from the words “therapeutics” and “diagnostics“. Thus, “theranostics” refers to the process of “diagnostic therapy” for individual patients. What exactly do we mean by this? … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: application, clinical, theranostics | 1 Comment »
The European Association of Urology (EAU) “Update on Prostate Cancer” meeting was held in Vienna, Austria, on Friday and Saturday, and Dr. Zachary Klaassen was again busy providing summary reports on presentations for UroToday. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, Diagnosis, PSA, screening, staging, testing | Leave a comment »
Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, dose, Jevtana, lower, mCRPC | Leave a comment »
According to an article in the journal Cancer, men with low-risk prostate cancer diagnosed and managed at high-volume hospitals are 3.6 times more likely to be managed on active surveillance than those managed at low-volume institutions. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, application, guidelines, variation | 2 Comments »
